Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2023-184845

Published: 2023

Journal Articles

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Alessandra Iurlo, Massimo Breccia, Fabio Stagno, Elisabetta Abruzzese, Fabrizio Pane, Immacolata Attolico, Paolo Sportoletti, Marco Cerrano, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Diletta Valsecchi, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Giuseppe Saglio, Gianantonio Rosti

Blood (2023) 142 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2023-180131

Published: 2023

Journal Articles

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Blood (2023) 142 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2023-177951

Published: 2023

Journal Articles

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Blood (2023) 142 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2023-173574

Published: 2023

Journal Articles

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Blood (2023) 142 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2023-178599

Published: 2023

Journal Articles

Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Fabio Stagno, Elisabetta Abruzzese, Alessandra Iurlo, Fabrizio Pane, Imma Attolico, Paolo Sportoletti, Patrizia Pregno, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Diletta Valsecchi, Aurelio Pio Nardozza, Paola Coco, Gianantonio Rosti, Giuseppe Saglio, Massimo Breccia

Blood (2022) 140 (Supplement 1): 9614–9616.

https://doi.org/10.1182/blood-2022-157700

Published: 2022

Journal Articles

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Matteo Piccini, Sofia Pilerci, Barbara Scappini, Francesco Mannelli, Gaia Ciolli, Andrea Pasquini, Laura Fasano, Elisa Quinti, Paola Guglielmelli, Carmela Mannarelli, Fabiana Pancani, Michela Zizza, Leonardo Signori, Alessandro M. Vannucchi, Giacomo Gianfaldoni

Blood (2022) 140 (Supplement 1): 9008–9009.

https://doi.org/10.1182/blood-2022-163212

Published: 2022

Journal Articles

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blood (2021) 138 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2021-153028

Published: 2021

Journal Articles

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Blood (2021) 138 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2021-147325

Published: 2021

Journal Articles

First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib

Massimo Breccia, Elisabetta Abruzzese, Fabio Stagno, Alessandra Iurlo, Fabrozio Pene, Immacolata Attolica, Paolo Sportoletti, Patrizia Pregno, Sara Galimberti, Barbara Scappini, Roberto M. Lemoli, Sergio Siragusa, Isabella Capodanno, Francesca Chiodi, Giuseppe Nicola Saglio, Gianantonio Rosti

Blood (2021) 138 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2021-145411

Published: 2021

Journal Articles

Glycosylphosphatidylinositol-specific T cells, IFN-γ-producing T cells, and pathogenesis of idiopathic aplastic anemia

Lucia Gargiulo, Yoshitaka Zaimoku, Barbara Scappini, Hiroyuki Maruyama, Rie Ohumi, Lucio Luzzatto, Shinji Nakao, Rosario Notaro

Blood (2017) 129 (3): 388–392.

https://doi.org/10.1182/blood-2016-09-740845

Published: 2017

Journal Articles

The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience

Blood (2016) 128 (22): 3951.

https://doi.org/10.1182/blood.V128.22.3951.3951

Published: 2016

Journal Articles

Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA)

Lucia Gargiulo, PhD, Yoshitaka Zaimoku, MD, Barbara Scappini, MD, Hiroyuki Maruyama, MD, Rie Ohumi, Lucio Luzzatto, MD, Shinji Nakao, MD PhD, Rosario Notaro, MD

Blood (2015) 126 (23): 2409.

https://doi.org/10.1182/blood.V126.23.2409.2409

Published: 2015

Journal Articles

Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?

Lara Aprile, Luca Puccetti, Sara Galimberti, Antonella Gozzini, Francesca Scarpini, Marzia Defina, Federica De Majo, Claudia Baratè, Anna Sicuranza, Veronica Candi, Barbara Scappini, Donatella Raspadori, Alessandro Gozzetti, Alberto Bosi, Mario Petrini, Monica Bocchia

Blood (2013) 122 (21): 1482.

https://doi.org/10.1182/blood.V122.21.1482.1482

Published: 2013

Journal Articles

Concomitant occurrence of BCR-ABL and JAK2 V617F mutation

Lisa Pieri, Ambra Spolverini, Barbara Scappini, Umberto Occhini, Silvia Birtolo, Alberto Bosi, Francesco Albano, Carmen Fava, Alessandro M. Vannucchi

Blood (2011) 118 (12): 3445–3446.

https://doi.org/10.1182/blood-2011-07-365007

Published: 2011

Journal Articles

Efficacy of Low Dose Clofarabine Plus Intermediate Dose Cytarabine In An Unselected AML Refractory/Relapsed Adult Population

Claudio Romani, MD, Emanuele Angelucci, MD, Barbara Scappini, MD, Mario Petrini, MD, Martina Pettinau, Filippo Marmont, Francesco Caracciolo, Ernesta Audiosio, MD, Alberto Bosi

Blood (2010) 116 (21): 4349.

https://doi.org/10.1182/blood.V116.21.4349.4349

Published: 2010

Journal Articles

High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients.

Barbara Scappini, MD, Giacomo Gianfaldoni, MD, Palmieri Salvatore, MD, Maria Chiara Susini, MD, Teresa Izzo, MD, Francesco Mannelli, MD, Giovanni Longo, MD, Rosa Fanci, MD, Felicetto Ferrara, MD, Alberto Bosi, MD

Blood (2009) 114 (22): 1060.

https://doi.org/10.1182/blood.V114.22.1060.1060

Published: 2009

Journal Articles

Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life

Riccardo Saccardi, Gian Luigi Mancardi, Alessandra Solari, Alberto Bosi, Paolo Bruzzi, Paolo Di Bartolomeo, Amedea Donelli, Massimo Filippi, Angelo Guerrasio, Francesca Gualandi, Giorgio La Nasa, Alessandra Murialdo, Francesca Pagliai, Federico Papineschi, Barbara Scappini, Alberto M. Marmont, for the Italian GITMO-Neuro Intergroup

Blood (2005) 105 (6): 2601–2607.

https://doi.org/10.1182/blood-2004-08-3205

Published: 2005

Journal Articles

The carboxy-terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic signal

Valeria Santini, Barbara Scappini, Zena K. Indik, Antonella Gozzini, Pierluigi Rossi Ferrini, Alan D. Schreiber

Blood (2003) 101 (11): 4615–4622.

https://doi.org/10.1182/blood-2002-07-2271

Published: 2003

NARROW

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib

Glycosylphosphatidylinositol-specific T cells, IFN-γ-producing T cells, and pathogenesis of idiopathic aplastic anemia

The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience

Auto-Reactive Glycosyl-Phosphatidyl-Inositol (GPI) Specific T Cells Are Present in Most Patients with Idiopathic Aplastic Anemia (IAA)

Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?

Concomitant occurrence of BCR-ABL and JAK2 V617F mutation

Efficacy of Low Dose Clofarabine Plus Intermediate Dose Cytarabine In An Unselected AML Refractory/Relapsed Adult Population

High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients.

Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life

The carboxy-terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic signal

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only